relatlimab (BMS-986016) / BMS 
Welcome,         Profile    Billing    Logout  
 4 Diseases   51 Trials   51 Trials   979 News 


«12345678910111213...1314»
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma
    Journal, IO biomarker:  Characterization of 405B8H3(D-E), a newly engineered high affinity chimeric LAG-3 antibody with potent antitumor activity. (Pubmed Central) -  Jun 11, 2023   
    Moreover, it could bind cynomolgus monkey (cyno) LAG-3 expressed on HEK293 cells with a higher affinity than the reference anti-LAG-3 antibody BMS-986016...Finally, 405B8H3(D-E) combined with anti-mPD-1-antibody showed effective therapeutic potential in the MC38 tumor mouse model. Therefore, 405B8H3(D-E) is likely to be a promising candidate therapeutic antibody for immunotherapy.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  Single-Agent PD-1 Blockade Is "Treatment of Choice" for Desmoplastic Melanoma. (Pubmed Central) -  Jun 5, 2023   
    Data from the phase II S1512 trial indicate that patients with inoperable metastatic desmoplastic melanoma are highly responsive to first-line pembrolizumab. As such, anti-PD-1 monotherapy, rather than current combinations such as nivolumab-relatlimab, should be considered for these patients.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Metastases:  Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma. (Pubmed Central) -  May 18, 2023   
    We describe the current status of combination of nivolumab+ relatlimab in the treatment of advanced melanoma patients based on the available data coming from pivotal clinical trials. The most important question to be answered is what would be the place of this novel combination in the treatment planning strategy.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial primary completion date, Metastases:  IMAGINE: Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (clinicaltrials.gov) -  May 11, 2023   
    P2,  N=21, Active, not recruiting, 
    The most important question to be answered is what would be the place of this novel combination in the treatment planning strategy. Trial primary completion date: Apr 2023 --> Mar 2024
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, Metastases:  The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. (Pubmed Central) -  May 8, 2023   
    While the safety profile is more favorable than that of ipilimumab plus nivolumab, no significant survival benefit has yet been demonstrated with the new combination over nivolumab monotherapy. The approval of relatlimab plus nivolumab by both the Food and Drug Administration and the European Medicines Agency expands the arsenal of treatment options for melanoma but raises new questions in clinical practice and a re-evaluation of currently established treatment standards and sequences.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Enrollment closed, Metastases:  CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) -  May 6, 2023   
    P2,  N=27, Active, not recruiting, 
    The approval of relatlimab plus nivolumab by both the Food and Drug Administration and the European Medicines Agency expands the arsenal of treatment options for melanoma but raises new questions in clinical practice and a re-evaluation of currently established treatment standards and sequences. Recruiting --> Active, not recruiting
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. (Pubmed Central) -  May 3, 2023   
    Prospective studies are therefore needed to determine if high levels of the LAG-3 checkpoint are responsible for resistance to anti-PD-1/PD-L1 or anti-CTLA-4 antibodies. Furthermore, a precision/personalized immunotherapy approach may require interrogating individual tumor immunograms to match patients to the right combination of immunotherapeutic agents for their malignancy.
  • ||||||||||  Adrenal insufficiency in patients on immune checkpoint inhibitors: () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4689;    
    Future prospective studies will be needed to confirm this finding. Physicians, particularly oncologists and endocrinologists, should have a high index of suspicion for adrenal insufficiency in patients on immune checkpoint inhibitors.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Factors associated with myocarditis in patients with cancer treated with immune checkpoint inhibitors. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4688;    
    Due to a low incidence among controls, rhabdomyolysis and myositis could not be included as covariates in adjusted analyses; however bivariate results showed strong associations between myocarditis and rhabdomyolysis or myositis. These findings suggest that co-occurrences of myositis, rhabdomyolysis, or hepatitis are associated with myocarditis and may originate from a more generalized ICI myopathy.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM). (On Demand | Hall A; Poster Bd # 361b) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2579;    
    P2
    Long-term outcomes of the CheckMate 204 study combining ipilimumab (ipi) (3mg/kg) plus nivo (1 mg/kg) for asymptomatic MBM reported an intracranial (IC) response in 54% of pts...Longitudinal research blood, tissue, and microbiome samples will be collected along with neurocognitive assessment and quality of life surveys. Clinical trial information: NCT05704647.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), fianlimab (REGN3767) / Regeneron, Sanofi
    A phase 3 trial comparing fianlimab (anti (On Demand | Hall A; Poster Bd # 358a) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2572;    
    P3
    The first analysis will be performed when 242 RFS events have been observed. Clinical trial information: NCT05608291.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases:  NCI-2018-01517: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma (clinicaltrials.gov) -  Apr 13, 2023   
    P2,  N=10, Active, not recruiting, 
    Standard adjuvant therapies can be safely administered in this setting. Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab (clinicaltrials.gov) -  Apr 6, 2023   
    P1,  N=24, Completed, 
    Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2024 Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Aug 2022 --> Feb 2023
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Journal:  Nivolumab Plus Relatlimab Is Safe and Efficacious in Pretreated Melanoma. (Pubmed Central) -  Apr 4, 2023   
    Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Aug 2022 --> Feb 2023 Nivolumab plus relatlimab has a manageable safety profile in patients with advanced pretreated melanoma.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    Trial completion date, Trial initiation date, Trial primary completion date, Checkpoint inhibition, Metastases:  Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors (clinicaltrials.gov) -  Mar 29, 2023   
    P1,  N=33, Not yet recruiting, 
    Nivolumab plus relatlimab has a manageable safety profile in patients with advanced pretreated melanoma. Trial completion date: Feb 2029 --> Jun 2029 | Initiation date: Feb 2023 --> Jun 2023 | Trial primary completion date: May 2027 --> Sep 2027
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Enrollment closed, Enrollment change, Tumor mutational burden, Metastases:  NCI-2018-01517: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma (clinicaltrials.gov) -  Mar 14, 2023   
    P2,  N=10, Active, not recruiting, 
    Together, these data show that TNRX-257 has drug-like properties and elicits strong anti-tumor efficacy, supporting its clinical development. Recruiting --> Active, not recruiting | N=20 --> 10
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    LAG-3 expression in advanced basal cell carcinoma (BCC) and tumor regression following combined PD-1/LAG-3 blockade () -  Mar 4, 2023 - Abstract #ISID2023ISID_1701;    
    This graduated increase in LAG-3 checkpoint expression after anti-PD-1 therapy lends support for coordinated immunosuppression. Furthermore, the baseline expression of LAG-3 in archival specimens and the pattern of display distinct from PD-1 suggests that LAG-3 may be a co-dominant or sub-dominant checkpoint in this tumor type, and supports future exploration of combined PD-1/LAG-3 blockade in patients with advanced BCC.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed, Checkpoint inhibition, Checkpoint block:  Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (clinicaltrials.gov) -  Mar 3, 2023   
    P1,  N=20, Active, not recruiting, 
    Furthermore, the baseline expression of LAG-3 in archival specimens and the pattern of display distinct from PD-1 suggests that LAG-3 may be a co-dominant or sub-dominant checkpoint in this tumor type, and supports future exploration of combined PD-1/LAG-3 blockade in patients with advanced BCC. Recruiting --> Active, not recruiting